Nucleic acid and polypeptide aptamers: A powerful approach to ligand discovery

Current Opinion in Pharmacology

Volumn 1, Issue 5, 2001, Pages 540-546

  James, William ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PEPTIDE NUCLEIC ACID;

ANIMAL; CHEMISTRY; COMBINATORIAL CHEMISTRY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; REVIEW;

ANIMAL; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMAN; LIGANDS; PEPTIDE NUCLEIC ACIDS;

EID: 0035486783     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00093-5     Document Type: Review

References (56)

1. Wentworth P, Janda K: Generating and analyzing combinatorial chemistry libraries. Curr Opin Biotechnol 1998, 9:109-115.
2. Houghten R, Wilson D, Pinilla C: Drug discovery and vaccine development using mixture-based synthetic combinatorial libraries. Drug Discov Today 2000, 5:276-285.
3. James W: Aptamers. In The Encyclopedia of Analytical Chemistry: Instrumentation and Applications. Edited by Myers R. Chichester: John Wiley; 2000, 4848-4871.
4. Brody EN, Gold L: Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000, 74:5-13.
5. Geyer CR, Brent R: Selection of genetic agents from random peptide aptamer expression libraries. Methods Enzymol 2000, 328:171-208.
6. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
7. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
8. Robertson DL, Joyce GF: Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 1990, 344:467-468.
9. Marshall KA, Ellington AD: In vitro selection of RNA aptamers. Methods Enzymol 2000, 318:193-214.
10. Hermann T, Westhof E: Docking of cationic antibiotics to negatively charged pockets in RNA folds. J Med Chem 1999, 42:1250-1261.
11. Cowan JA, Ohyama T, Wang D, Natarajan K: Recognition of a cognate RNA aptamer by neomycin B: quantitative evaluation of hydrogen bonding and electrostatic interactions. Nucleic Acids Res 2000, 28:2935-2942.
12. Hermann T, Patel DJ: Adaptive recognition by nucleic acid aptamers. Science 2000, 287:820-825.
13. Kotia RB, Li L, McGown LB: Separation of nontarget compounds by DNA aptamers. Anal Chem 2000, 72:827-831.
14. Romig T, Bell C, Drolet D: Aptamer affinity chromatography: combinatorial chemistry applied to protein purification. J Chromatogr 1999, 731:275-284.
15. Gebhardt K, Shokraei A, Babaie E, Lindqvist BH: RNA aptamers to S-adenosylhomocysteine: kinetic properties, divalent cation dependency, and comparison with anti-S-adenosylhomocysteine antibody. Biochemistry 2000, 39:7255-7265.
16. Seiwert SD, Stines Nahreini T, Aigner S, Ahn NG, Uhlenbeck OC: RNA aptamers as pathway-specific MAP kinase inhibitors. Chem Biol 2000, 7:833-843.
17. Lebruska LL, Maher LJ III: Selection and characterization of an RNA decoy for transcription factor NF-κB. Biochemistry 1999, 38:3168-3174.
18. Mayer G, Blind M, Nagel W, Bohm T, Knorr T, Jackson CL, Kolanus W, Famulok M: Controlling small guanine-nucleotide-exchange factor function through cytoplasmic RNA intramers. PNAS 2001, 98:4961-4965. With the aim of obtaining an inhibitor of small guanine-nucleotide-exchange factors (GEFs) that would complement brefeldin A, a widely used inhibitor of the large GEFs, the authors isolated a specific aptamer that had effects in cells analogous to the effects of dominant mutations of a known small GEF.
19. Hesselberth JR, Miller D, Robertus J, Ellington AD: In vitro selection of RNA molecules that inhibit the activity of ricin A-chain. J Biol Chem 2000, 275:4937-4942.
20. Kensch O, Connolly BA, Steinhoff HJ, McGregor A, Goody RS, Restle T: HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J Biol Chem 2000, 275:18271-18278. The authors isolated a pseudoknot RNA aptamer (i.e. with a specific tertiary structure element) that binds to the NA binding-site of HIV-1 reverse transcriptase with similar association kinetics to the natural substrate but with extremely slow dissociation rates. This results in mid-picomolar affinity and high selectivity against the homologous enzyme of other retroviruses.
21. Fukuda K, Vishnuvardhan D, Sekiya S, Hwang J, Kakiuchi N, Taira K, Shimotohno K, Kumar PK, Nishikawa S: Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur J Biochem 2000, 267:3685-3694.
22. Toulme JJ: Aptamers: selected oligonucleotides for therapy. Curr Opin Mol Ther 2000, 2:318-324.
23. White RR, Sullenger BA, Rusconi CP: Developing aptamers into therapeutics. J Clin Invest 2000, 106:929-934.
24. Rusconi CP, Yeh A, Lyerly HK, Lawson JH, Sullenger BA: Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost 2000, 84:841-848.
25. Rhodes A, Deakin A, Spaull J, Coomber B, Aitken A, Life P, Rees S: The generation and characterization of antagonist RNA aptamers to human oncostatin M. J Biol Chem 2000, 275:28555-28561.
26. Dougan H, Lyster DM, Vo CV, Stafford A, Weitz JI, Hobbs JB: Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol 2000, 27:289-297.
27. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N: 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998, 273:20556-20567.
28. Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC et al.: Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000, 17:1502-1510.
29. Tucker C, Chen L, Judkins M, Farmer JA, Gill S, Drolet D: Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr 1999, 732:203-212.
30. Watson SR, Chang YF, O'Connell D, Weigand L, Ringquist S, Parma DH: Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev 2000, 10:63-75.
31. Leppanen O, Janjic N, Carlsson MA, Pietras K, Levin M, Vargeese C, Green LS, Bergqvist D, Ostman A, Heldin CH: Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 2000, 20:E89-E95.
32. Wang J, Jiang H, Liu F: In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA 2000, 6:571-583.
33. Jeong S, Eom T, Kim S, Lee S, Yu J: In vitro selection of the RNA aptamer against the Sialyl Lewis X and its inhibition of the cell adhesion. Biochem Biophys Res Commun 2001, 281:237-243.
34. Homann M, Göringer HU: Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nucleic Acids Res 1999, 27:2006-2014. The authors selected NA aptamers against whole, live trypanosomes. The parasites are covered with a dense layer of antigenically variable protein that prevents the immune response from mounting an effective defense. The aptamers were able to penetrate a pocket to reach a conserved site found on antigenically distinct trypanosomes, a feat that natural antibodies are unable to achieve.
35. Kato T, Yano K, Ikebukuro K, Karube I: Bioassay of bile acids using an enzyme-linked DNA aptamer. Analyst 2000, 125:1371-1373.
36. Hesselberth J, Robertson MP, Jhaveri S, Ellington AD: In vitro selection of nucleic acids for diagnostic applications. J Biotechnol 2000, 74:15-25.
37. Jhaveri S, Rajendran M, Ellington AD: In vitro selection of signaling aptamers. Nat Biotechnol 2000, 18:1293-1297.
38. Yamamoto R, Baba T, Kumar PK: Molecular beacon aptamer fluoresces in the presence of Tat protein of HIV-1. Genes Cells 2000, 5:389-396. The authors use an aptamer raised against HIV-1 Tat protein (with 100-fold higher affinity than the natural ligand) to detect Tat. A fluorochrome and a quencher were coupled to the two ends of the aptamer and the conformation change upon binding to Tat relieved quenching, generating fluorescence.
39. Lee M, Walt DR: A fiber-optic microarray biosensor using aptamers as receptors. Anal Biochem 2000, 282:142-146.
40. Golden MC, Collins BD, Willis MC, Koch TH: Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J Biotechnol 2000, 81:167-178.
41. Ohtsuki T, Kimoto M, Ishikawa M, Mitsui T, Hirao I, Yokoyama S: Unnatural base pairs for specific transcription. PNAS 2001, 98:4922-4925.
42. Gourlain T, Sidorov A, Mignet N, Thorpe SJ, Lee SE, Grasby JA, Williams DM: Enhancing the catalytic repertoire of nucleic acids. II. Simultaneous incorporation of amino and imidazolyl functionalities by two modified triphosphates during PCR. Nucleic Acids Res 2001, 29:1898-1905.
43. Sidhu S: Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000, 11:610-616.
44. Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R: Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 1996, 380:548-550.
45. Blum JH, Dove SL, Hochschild A, Mekalanos JJ: Isolation of peptide aptamers that inhibit intracellular processes. Proc Natl Acad Sci USA 2000, 97:2241-2246.
46. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F: Induction of apoptosis in human papillomavirus-positive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000, 97:6693-6697. A good example of the method of in vivo selection of constrained peptide aptamers by a modified two-hybrid approach.
47. Colas P, Cohen B, Ferrigno PK, Silver PA, Brent R: Targeted modification and transportation of cellular proteins. Proc Natl Acad Sci USA 2000, 97:13720-13725. A powerful study describing two innovations. First, intense in vitro mutagenesis is used to improve the affinity of a peptide aptamer against Cdk2 from 100 nM to 5 nM. Second, intracellular Cdk2 is targeted for proteolytic turnover by coupling the peptide aptamer to the hect domain of ubiquitin ligase. This technology provides a genera approach for the generation of phenotypic knockouts, in which the gene product of interest is inhibited at the protein level.
48. Hanes J, Plückthun A: In vitro selection and evolution of functional proteins by using ribosome display. PNAS 1997, 94:4937-4942.
49. Jermutus L, Honegger A, Schwesinger F, Hanes J, Pluckthun A: Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci USA 2001, 98:75-80.
50. Hanes J, Schaffitzel C, Knappik A, Plückthun A: Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol 2000, 18:1287-1292.
51. Roberts RW, Szostak JW: RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc Natl Acad Sci USA 1997, 94:12297-12302.
52. Cho G, Keefe AD, Liu R, Wilson DS, Szostak JW: Constructing high complexity synthetic libraries of long ORFs using in vitro selection. J Mol Biol 2000, 297:309-319.
53. Liu R, Barrick JE, Szostak JW, Roberts RW: Optimized synthesis of RNA-protein fusions for in vitro protein selection. Methods Enzymol 2000, 318:268-293.
54. Wilson DS, Keefe AD, Szostak JW: The use of mRNA display to select high-affinity protein-binding peptides. PNAS 2001, 98:3750-3755. A tour de force from the guru of aptamerology using a range of ingenious ways of getting round some of the problems thrown up by the remarkable mRNA display method. One trick used was to avoid the unwanted selection of RNA aptamers during partitioning by first reverse-transcribing the mRNA-oligopeptide fusion, so that the cDNA-mRNA hybrid effectively prevented any tendency of the mRNA to fold into any interesting shapes.
55. Keefe AD, Szostak JW: Functional proteins from a random-sequence library. Nature 2001, 410:715-718.
56. Huizenga DE, Szostak JW: A DNA aptamer that binds adenosine and ATP. Biochemistry 1995, 34:656-665.